© 2022 by the AGA Institute; Current treatment algorithms in inflammatory bowel disease (IBD) rely on a “trial and error” approach, and therefore, patients may receive ineffective and costly therapy for many months, with associated risks. Furthermore, after failure of the first biologic, response rates to second-line therapies drop considerably. Personalized medicine, which seeks to identify biomarkers that pre...
N/A.; N/A.
N/A.; N/A.
N/A; n/a
n/a; n/a